A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children's Oncology Group prospective study

Sheri L. Spunt(BVI (United States)), Douglas S. Hawkins(Seattle Children's Hospital), Emily Hibbitts(University of Florida), William H. Meyer(Lawrence Livermore National Laboratory), Lynn Million(VA Palo Alto Health Care System), Simon C. Kao(University of Iowa), James R. Anderson(Merck & Co., Inc., Rahway, NJ, USA (United States)), David M. Parham(Children's Hospital of Los Angeles), Roseanne Speights(St. Jude Children's Research Hospital), Alberto S. Pappo(St. Jude Children's Research Hospital), M. Beth McCarville(St. Jude Children's Research Hospital), R. Lor Randall(University of California Davis Medical Center), Andrea Hayes‐Jordan(The University of Texas MD Anderson Cancer Center), Suzanne L. Wolden(Memorial Sloan Kettering Cancer Center), Jennifer O. Black(Children's Hospital Colorado), Ellen Kawashima(Children's Oncology Group), Jing Tian(Harbin Medical University), Cheryl M. Coffin(University of Utah), Fran Laurie(University of Massachusetts Chan Medical School), Yueh-Yun Chi(University of Southern California), Stephen X. Skapek(Duke University)
The Lancet Oncology
November 27, 2019
Cited by 182


Related Papers